Alnylam Pharmaceuticals Affirms FY2026 Sales Guidance of $5.300B-$5.800B vs $5.545B Est

Benzinga Newsdesk www.benzinga.com Negative 75.0%

Neg 75% Neu 0% Pos 0%

Alnylam Pharmaceuticals (NASDAQ:ALNY) affirms FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.300 billion-$5.800 billion vs $5.545 billion estimate.